However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months. 
Because the ultimate goal of a steroid cycle is to increase strength and muscle size, the associated spike in estrogen which accompanies steroids such as Testosterone is considered undesirable. In order to disassociate the two effects, two classes of drug are used. Medications such as Nolvadex or Clomid target the estrogen receptors. They make it more difficult for the estrogen to exert it’s influence within the body thus allowing the testosterone to act more freely. The second class is aromatase inhibitors such as Femara. They target the aromatase enzyme itself in order to prevent the production of estrogen in the first place. Sometimes, it’s not always clear which option you should go with or even what the differences are between the two. Lets clear that up a little.